Clinical trial
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
NCT05204628
Study timeline
Study start (estimated)2022-02-07Date precision: day
Registry last updated2022-01-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
XZP-3621DRUG
CrizotinibDRUG · verified · RxNorm: crizotinib
Sponsors & collaborators
Xuanzhu Biopharmaceutical Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05204628 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.